Free Trial

PureTech Health (LON:PRTC) Shares Up 14.2% - Time to Buy?

PureTech Health logo with Medical background

Key Points

  • PureTech Health plc shares surged by 14.2% on Friday, rising to GBX 121.50 ($1.65) after trading as high as GBX 123.80 ($1.68).
  • Insider Bharatt Chowrira purchased 167,739 shares of the company at an average price of GBX 1 per share, indicating strong insider confidence in the firm.
  • PureTech Health is a clinical-stage biopharma company focused on developing medicines for nervous, gastrointestinal, and immune system disorders, utilizing a microbiome immune system drug-discovery platform.
  • MarketBeat previews top five stocks to own in October.

PureTech Health plc (LON:PRTC - Get Free Report) was up 14.2% during trading on Friday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares were traded during mid-day trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Trading Up 14.2%

The company has a market capitalization of £293.65 million, a P/E ratio of 714.71 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The company has a 50-day simple moving average of GBX 129.46 and a 200 day simple moving average of GBX 129.76.

Insider Buying and Selling

In other PureTech Health news, insider Bharatt Chowrira acquired 167,739 shares of PureTech Health stock in a transaction on Thursday, July 3rd. The shares were bought at an average price of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is currently owned by corporate insiders.

About PureTech Health

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Further Reading

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.